Defining the role of TORC1/2 in multiple myeloma.
暂无分享,去创建一个
Charles P. Lin | C. Rommel | S. Rodig | A. Roccaro | A. Sacco | A. Azab | F. Azab | H. Ngo | Phong Quang | P. Maiso | I. Ghobrial | Yi Liu | P. Ren | Michael B Martin | Yong Zhang | B. Morgan | Yang Liu | Brittany L. Morgan | Pingda Ren | Michael B. Martin
[1] C. Parent,et al. Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. , 2011, Blood.
[2] J. Gera,et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. , 2010, Blood.
[3] J. de la Rubia,et al. DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma? , 2010, Leukemia & lymphoma.
[4] S. Fitter,et al. NVP‐BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] C. Parent,et al. Ras-mediated activation of the TORC2–PKB pathway is critical for chemotaxis , 2010, The Journal of cell biology.
[6] K. Anderson,et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. , 2010, Blood.
[7] Pascale G. Charest,et al. A Ras signaling complex controls the RasC-TORC2 pathway and directed cell migration. , 2010, Developmental cell.
[8] Nahum Sonenberg,et al. Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.
[9] Jing Chen,et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.
[10] Charles P. Lin,et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. , 2010, Blood.
[11] Charles P. Lin,et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. , 2009, Blood.
[12] Yasodha Natkunam,et al. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens , 2009, Nature Medicine.
[13] J. Blenis,et al. Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.
[14] D. Sabatini,et al. DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.
[15] Charles P. Lin,et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. , 2009, Blood.
[16] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[17] Robbie Loewith,et al. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.
[18] D. Chauhan,et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. , 2008, Blood.
[19] S. Lonial,et al. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. , 2007, Future oncology.
[20] T. Hideshima,et al. Combination Mammalian Target of Rapamycin Inhibitor Rapamycin and HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Has Synergistic Activity in Multiple Myeloma , 2006, Clinical Cancer Research.
[21] Huajun Yan,et al. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade , 2005, Molecular Cancer Therapeutics.
[22] F. Moatamed,et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. , 2004, Blood.
[23] Paul Richardson,et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. , 2004, Blood.
[24] R. Bataille,et al. The Magnitude of Akt/Phosphatidylinositol 3′-Kinase Proliferating Signaling Is Related to CD45 Expression in Human Myeloma Cells1 , 2004, The Journal of Immunology.
[25] J. Blenis,et al. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression , 2004, Oncogene.
[26] K. Nilsson,et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. , 2004, Blood.
[27] K. Vanderkerken,et al. Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model , 2004, British Journal of Cancer.
[28] A. Lichtenstein,et al. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway , 2003, Oncogene.
[29] J. Slingerland,et al. Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression , 2003, Cell cycle.
[30] R. Bookstein,et al. Mutations to CCI-779 PTEN Enhanced Sensitivity of Multiple Myeloma Cells Containing Updated Version , 2002 .
[31] B. Monia,et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells , 2002, Oncogene.
[32] D. Chauhan,et al. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma , 2001, Oncogene.
[33] N. Sonenberg,et al. Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy , 2012, BioDrugs.
[34] P. Devreotes,et al. Assays for chemotaxis and chemoattractant-stimulated TorC2 activation and PKB substrate phosphorylation in Dictyostelium. , 2009, Methods in molecular biology.
[35] D. Chauhan,et al. Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.